Amgen has announced plans to invest an additional $300 million in its biologics manufacturing facility in Juncos, Puerto Rico, following up on its earlier $650-million investment in the same facility, which was announced in September 2025. 

Amgen’s latest investment builds on its broader US expansion strategy. This includes a $1.5-billion investment at its biomanufacturing site in Holly Springs, North Carolina, which includes $1 billion for a second drug-substance biomanufacturing facility. The company also announced  a $900-million expansion of its Ohio manufacturing facility in April 2025. The company is also investing $600 million for a new Center for Science and Innovation at its global headquarters in Thousand Oaks, California. 

Source: Amgen